Cell death pathways in Parkinson's disease: Role of mitochondria

Antioxidants and Redox Signaling

Volumn 11, Issue 9, 2009, Pages 2135-2149

  Yao, Zhi ^a   Wood, Nicholas W ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CALCIUM ION; CREATINE; DJ 1 PROTEIN; GENOMIC DNA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARAQUAT; PARKIN; PHOSPHOTRANSFERASE; PROTEIN PINK1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SERINE PROTEINASE OMI; UBIDECARENONE; UNCLASSIFIED DRUG;

APOPTOSIS; CALCIUM METABOLISM; CLINICAL TRIAL; COMPLEX I DEFICIENCY; DRUG MECHANISM; GENE DELETION; GENE MUTATION; HUMAN; LEWY BODY; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MITOCHONDRIAL DNA DISORDER; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUBSTANTIA NIGRA;

CELL DEATH; CELL NUCLEUS; DNA; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 68949209958     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2624     Document Type: Review

References (180)

1. Abramov AY, Canevari L, and Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23:5088-5095, 2003.
2. Abramov AY, Canevari L, and Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24: 565-575, 2004.
3. Andres RH, Ducray AD, Perez-Bouza A, Schlattner U, Huber AW, Krebs SH, Seiler RW, Wallimann T, and Widmer HR. Creatine supplementation improves dopaminergic cell survival and protects against MPP+ toxicity in an organotypic tissue culture system. Cell Transplant 14: 537-550, 2005.
4. Andres RH, Ducray AD, Schlattner U, Wallimann T, and Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull 76: 329-343, 2008.
5. Baloh RH, Salavaggione E, Milbrandt J, and Pestronk A. Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch Neurol 64: 998-1000, 2007.
6. Baloh RH, Schmidt RE, Pestronk A, and Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 27: 422-430, 2007.
7. Bandmann O, Sweeney MG, Daniel SE, Marsden CD, and Wood NW. Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 244: 262-265, 1997.
8. Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, Canet-Aviles R, Miller DW, MCLendon C, Strand C, Leonard AJ, bou-Sleiman PM, Healy DG, Ariga H, Wood NW, de SR, Revesz T, Hardy JA, and Lees AJ. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127: 420-430, 2004.
9. Beal MF, Matthews RT, Tieleman A, and Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783: 109-114, 1998.
10. Beilina A, Van Der BM, Ahmad R, Kesavapany S, Miller DW, Petsko GA, and Cookson MR. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 102: 5703-5708, 2005.
11. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Muller-Myhsok B, Gasser T, Tatsch K, and Klopstock T. Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology 67: 1262-1264, 2006.
12. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betty J, Klopstock T, Taylor RW, and Turnbull DM. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517, 2006.
13. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, and Greenamyre JT. Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22: 404-420, 2006.
14. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306, 2000.
15. Bezprozvanny I and Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 322: 1310-1317, 2004.
16. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD, Jr., and Turnbull DM. Mitochondrial function in Parkinson's disease. Lancet 2: 49, 1989.
17. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD, Jr., and Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 104: 203-208, 1991.
18. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G, and Heutink P. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24: 159-160, 2003.
19. Buttner S, Bitto A, Ring J, Augsten M, Zabrocki P, Eisenberg T, Jungwirth H, Hutter S, Carmona-Gutierrez D, Kroemer G, Windericks J, and Madeo F. Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. J Biol Chem 283: 7554-7560, 2008.
20. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, and Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101: 9103-9108, 2004.
21. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de YJ, and Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97: 934-946, 2006.
22. Cassarino DS, Parks JK, Parker WD, Jr., and Bennett JP, Jr. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453: 49-62, 1999.
23. Chan DC. Mitochondria: Dynamic organelles in disease, aging, and development. Cell 125: 1241-1252, 2006.
24. Chen CM, Kuan CC, Lee-Chen GJ, and Wu YR. Mitochondrial DNA polymorphisms and the risk of Parkinson's disease in Taiwan. J Neural Transm 114: 1017-1021, 2007.
25. Ciechanover A and Schwartz AL. The ubiquitin-protea some pathway: The complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95: 2727-2730, 1998.
26. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Soel JH, Yoo SJ, Hay BA, and Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162-1166, 2006.
27. Cleren C, Starkov AA, Calingasan NY, Lorenzo BJ, Chen J, and Beal MF. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiol Dis 20: 701-708, 2005.
28. Cosi C, Colpaert F, Koek W, Degryse A, and Marien M. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res 729: 264-269, 1996.
29. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M, and Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12: 517-526, 2003.
30. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, TIeu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, and Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99: 14524-14529, 2002.
31. de Lau LM and Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535, 2006.
32. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Starie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, and Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26: 207-210, 2000.
33. Deng H, Dodson MW, Huang H, and Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105: 14503-14508, 2008.
34. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, and Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089-9100, 2008.
35. Ernster L and Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271: 195-204, 1995.
36. Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken HH, Gasser R, Kruger R, Winklehofer KF, Vogel F, Reichert AS, Augurger G, Kahle PH, Schmid B, and Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27: 12413-12418, 2007.
37. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah F, and Chesselet MF. Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of alpha-synuclein over-expression. Synapse 61: 991-1001, 2007.
38. Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma 17: 843-855, 2000.
39. Forno LS, Langston JW, DeLanney LE, and Irwin I. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 448: 150-157, 1988.
40. Furukawa K, Matsuzaki-Kobayashi M, Hasegawa T, Kikuchi A, Sugeno N, Itoyama Y, Wang Y, Yao PJ, Bushlin I, and Takeda A. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem 97: 1071-1077, 2006.
41. Gandhi S, Muqit MM, Stanyer L, Healy DG, bou-Sleiman PM, Hargreaves J, Heales S, Ganguly M, Parsons L, Lees AJ, Latchman DS, Holton JL, Wood NW, and Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 129: 1720-1731, 2006.
42. Gautier CA, Kitada T, and Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 105: 11364-11369, 2008.
43. Ghezzi D, Marelli C, Achilli A, Goldwurm S, Pezzoli G, Barone P, Pellecchia MT, Stanzione P, Brusa I, Bentivoglio AR, Bonuccelli U, Petrozzi I, Abbruzzese G, Marchese R, Cortelli P, Grimaldi D, Martinelli P, Ferrarese C, Garvaglia B, Sangiogi S, Carelli V, Torroni A, Albanese A, and Zeviani M. Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet 13: 748-752, 2005.
44. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Torjanowski JQ, and Van DV. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59: 315-322, 2006.
45. Gilks WP, bou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, and Wood NW. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-416, 2005.
46. Giordana MT, D'Agostino C, Albani G, Mauro A, Di FA, Antonini A, and Bonifati V. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov Disord 22: 275-278, 2007.
47. Glater EE, Megeath LJ, Stowers RS, and Schwarz TL. Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent. J Cell Biol 173: 545-557, 2006.
48. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Holch W, Prokisch H, and Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15: 223-232, 2006.
49. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson L, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, and Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278: 43628-43635, 2003.
50. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, and Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45: 489-496, 2005.
51. Greene JC, Whitworth AJ, Andrews LA, Parker TJ, and Pallanck LJ. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet 14: 799-811, 2005.
52. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, and Cookson MR. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341, 2006.
53. Gu M, Cooper JM, Taanman JW, and Schapira AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44: 177-186, 1998.
54. Guo X, Macleod GT, Wellington A, Hu F, Panchumarthi S, Schoenfield M, Marin L, Charlton MP, Atwood NL, and Zinsmaier KE. The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. Neuron 47: 379-393, 2005.
55. Haque ME, Thomas KJ, D'Souza C, Callaghan S, Kitada T, Slack RS, Fraser P, Cookson MR, Tandon A, and Park DS. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci USA 105: 1716-1721, 2008.
56. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, and Hirsch EC. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97: 2875-2880, 2000.
57. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, and Hirsch EC. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21: 2247-2255, 2001.
58. Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M, Friguet B, and Hirsch EC. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86: 1297-1307, 2003.
59. Huerta C, Castro MG, Coto E, Blazquez M, Ribacoba R, Guisasola LM, Salvador C, Martinez C, Lahoz CH, and Alvarez V. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J Neurol Sci 236: 4954, 2005.
60. Ikebe S, Tanaka M, Ohno K, Sato W, and Hattori K. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170: 1044-1048, 1990.
61. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos ML, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, and Garcia de YJ. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12: 2277-2291, 2003.
62. Jackson-Lewis V, Jakowec M, Burke RE, and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257-269, 1995.
63. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, and Alessi DR. LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317, 2007.
64. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, and Mouradian MM. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci USA 102: 9691-9696, 2005.
65. Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, and Kanthasamy AG. Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: Relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci 18: 1387-1401, 2003.
66. Keeney PM, Xie J, Capaldi RA, and Bennett JP, Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256-5264, 2006.
67. Khan NL, Brooke DJ, Pavase N, Sweeney NG, Wood NW, Lees AJ, and Pircini P. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F] dopa PET and clinical study. Brain 125: 2248-2256, 2002.
68. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham. A, You-Ten AH, Kalia SK, Horne P, Westaway D, Lozano AM, Anisman H, Park DS, and Mak TW. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102: 5215-5220, 2005.
69. Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, and Chung J. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun 377: 975-980, 2008.
70. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Tokochi M, Mizuno Y, and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608, 1998.
71. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, Bonzi P, Zhang C, Pothos EN, and Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci USA 104: 11441-11446, 2007.
72. Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, and Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21: 541-548, 2006.
73. Kopin IJ. MPTP: An industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. Environ Health Perspect 75: 45-51, 1987.
74. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, and Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11: 211-1213, 2000.
75. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, and Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38: 518-520, 2006.
76. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19: 312-318, 1996.
77. Krige D, Carroll MT, Cooper JM, Marsden CD, and Schapira AH. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32: 782-788, 1992.
78. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H, and Matsumoto T. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15: 883-895, 2006.
79. Langston JW, Ballard P, Tetrud JW, and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980, 1983.
80. Lee dY, Lee KS, Lee HJ, Noh YH, Kim DH, Lee JY, Cho SH, TOon OJ, Lee WB, Kim KY, Chung YH, and Kim 22. Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur J Cell Biol 87: 389-397, 2008.
81. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey F, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehujia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, and Polymeropoulos MH. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452, 1998.
82. Lotharius J, and Brundin P. Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3: 932-942, 2002.
83. Luzon-Toro B, Rubio de la TE, Delgado A, Perez-Tur J, and Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16: 2031-2039, 2007.
84. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, and Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593, 2006.
85. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, and Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115: 333-342, 1992.
86. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, and Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. J Biol Chem 277: 1641-1644, 2002.
87. Manning-Bog AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, Langston JW, and Di Monte DA. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60: 256-260, 2006.
88. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, and Lee MK. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26: 41-50, 2006.
89. Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, Abiun A, Grau E, Geppert M, Livi GP, Creasy CL, Martin A, Hargreaves I, Heales SJ, Okada H, Brandner S, Schulz JB, Mak T, and Downward J. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 24: 9848-9862, 2004.
90. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, and Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157: 142-149, 1999.
91. McNaught KS, Belizaire R, Isacson O, Jenner P, and Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179: 38-46, 2003.
92. McNaught KS, Perl DP, Brownell AL, and Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56: 149-162, 2004.
93. Mitsumoto A and Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 35: 885-893, 2001.
94. Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, Shimo-Nakanishi Y, Urabe T, Tamada M, Tamayose K, Shimada T, Miura M, and Mizuno Y. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 98: 10918-10923, 2001.
95. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, and Nagatsu T. bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 215: 137-139, 1996.
96. Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N. Mizumo Y, Dawson TM, and Dawson VL. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 14: 71-84, 2005.
97. Muqit MM, bou-Sleiman PM, Saurin AT, Harvey K, Gandhi S, Deas E, Eaton S, Payne S, Venner K, Matilla A, Healy DG, Gilks WP, Lees AJ, Holton J, Revesz T, Parker PJ, Harvey RJ, Wood NW, and Latchman DS. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem 98: 156-169, 2006.
98. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, and Ariga H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231: 509-513, 1997.
99. Nicklas WJ, Vyas I, and Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508, 1985.
100. Nicotra A and Parvez SH. Cell death induced by MPTP, a substrate for monoamine oxidase B. Toxicology 153: 157-166, 2000.
101. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68: 20-28, 2007.
102. NINDS NET-PD Investigators. A randomized, doubleblind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671, 2006.
103. Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T< Sato K, Kuroda R, Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizumo Y, and Hattori N. Clinical heterogeneity of alphasynuclein gene duplication in Parkinson's disease. Ann Neurol 59: 298-309, 2006.
104. Olichon A, Emorine LJ, Descoins E, Pelloquin L, Brichese L, Gas N, Guillou E, Delettre C, Valette A, Hamel CP, Ducommun B, Lenaers G, and Belenguer P. The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space. FEBS Lett 523: 171-176, 2002.
105. Orth M, Tabrizi SJ, Schapira AH, and Cooper JM. Alpha-synuclein expression in HEK293 cells enhances themitochondrial sensitivity to rotenone. Neurosci Lett 351: 29-32, 2003.
106. Packer MA, Miesel R, and Murphy MP. Exposure to the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and nitric oxide simultaneously causes cyclosporin A-sensitive mitochondrial calcium efflux and depolarisation. Biochem Pharmacol 51: 267-273, 1996.
107. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munian A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de SR, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, and Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600, 2004.
108. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614-18622, 2004.
109. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strettmatter WJ, and Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736, 2002.
110. Parihar MS, Parihar A, Fujita M, Hashimoto M, and Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 65: 1272-1284, 2008.
111. Park J, Lee G and Chung J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem Biophys Res Commun 378: 518-523, 2009.
112. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, and Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441: 1157-1161, 2006.
113. Parker WD, Jr., Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723, 1989.
114. Parker WD, Jr., Parks JK, and Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 1189: 215-218, 2008.
115. Penn AM, Roberts T, Hodder J, Allen PS, Zhu G, and Martin WR. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45: 2097-2099, 1995.
116. Perier C, Bove J, Wu DC, Dehay B, Choi DK, Jackson-Lewis V, Rathke-Hartlieb S, Bouillet P, Strasser A, Schulz JB, Przwedborski S, and Vila M. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci USA 104: 8161-8166, 2007.
117. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, and Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA 102: 19126-19131, 2005.
118. Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, Wang L, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, and Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 280: 34025-34032, 2005.
119. Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins M, and Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9: 1243-1252, 2007.
120. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Bowyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lassarini AM, DUvoisin RC, Di JG, Golbe LI, and Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997.
121. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, and Pallanck LJ. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105: 1638-1643, 2008.
122. Pridgeon JW, Olzmann JA, Chin LS, and Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5: e172, 2007.
123. Przedborski S. Neuroinflammation and Parkinson's disease. Handb Clin Neurol 83: 535-551, 2007.
124. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens ML, and Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 1184-1191, 2006.
125. Rizzu P, Hinkle DA, Zhukareva V, Bonifati V, Severijnen LA, Martinez D, Ravid R, Kamphorst W, Eberwine JH, Lee VM, Trojanowski JQ, and Heutink P. DJ-1 colocalizes with tau inclusions: A link between parkinsonism and dementia. Ann Neurol 55: 113-118, 2004.
126. Ross OA, Soto AI, Vilarino-Guell C, Heckman MG, Diehl NN, Hulihan MM, Aasly JO, Sando S, Gibson JM, Lynch T, Krygowska-Wajs A, Opala G, Bareikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, and Farrer MJ. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord 14: 539-543, 2008.
127. Sakata E, Yamaguchi Y, Kurimoto E, Kikuchi J, Yokoyama S, Yamada S, Kawahara H, Yokosawa H, Hattori N, Mizuno Y, Tanaka K, and Kato K. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep 4: 301-306, 2003.
128. Schapira AH. Oxidative stress in Parkinson's disease. Neuropathol Appl Neurobiol 21: 3-9, 1995.
129. Schapira AH. Etiology of Parkinson's disease. Neurology 66: S10-S23, 2006.
130. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269, 1989.
131. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, and Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145, 1990.
132. Sherer TB, Kim JH, Betarbet R, and Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179: 9-16, 2003.
133. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305, 2000.
134. Shults CW, Beal MF, Fontaine D, Nakano K, and Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 50: 793-795, 1998.
135. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Permutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, and Lew M. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550, 2002.
136. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, and Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14: 3477-3492, 2005.
137. Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, and Cheng HC. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15: 3251-3262, 2006.
138. Simon-Sanchez J, and Singleton AB. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet 17: 1988-1993, 2008.
139. Singer TP, Salach JI, Castagnoli N, Jr., and Trevor A. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem J 235: 785-789, 1986.
140. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, and Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233, 2006.
141. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, and Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 102: 18676-18681, 2005.
142. Song DD, Shults CW, Sisk A, Rockenstein E, and Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 186: 158-172, 2004.
143. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388: 839-840, 1997.
144. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Muller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, and Kruger R. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14: 2099-2111, 2005.
145. Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, DIng Q, Chen Q, Bruce-Keller AJ, and Keller JN. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 279: 20699-20707, 2004.
146. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, and Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8: 613-621, 2001.
147. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, and Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40: 663-671, 1996.
148. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5: 213-218, 2004.
149. Tan JM and Dawson TM. Parkin blushed by PINK1. Neuron 50: 527-529, 2006.
150. Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH, Xia K, and Zhang Z. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15: 1816-1825, 2006.
151. Tatton NA and Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77: 1037-1048, 1997.
152. Taylor DJ, Krige D, Barnes PR, Kemp GJ, Carroll MT, Mann VM, Cooper JM, Marsden CD, and Schapira AH. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. J Neurol Sci 125: 77-81, 1994.
153. Taymans JM, Van den HC, and Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98: 951-961, 2006.
154. Testa CM, Sherer TB, and Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134: 109-118, 2005.
155. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, and Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for Parkinson's disease. J Neurosci 20: 9207-9214, 2000.
156. Unoki M and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20: 4457-4465, 2001.
157. Valente EM, bou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del TD, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Augurger G, and Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160, 2004.
158. Van Den BL, Van DP, Bogaert E, and Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 1068-1082, 2006.
159. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajuch JM, McLaurin AC, Middleton JT, Scott BL, Schmechel DE, Pericak-Vance MA, and Vance JM. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 72: 804-811, 2003.
160. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98: 2837-2842, 2001.
161. Voges D, Zwickl P, and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068, 1999.
162. Vyas S, Javoy-Agid F, Herrero MT, Strada O, Boissiere F, Hibner U, and Agid Y. Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders. J Neurochem 69: 223-231, 1997.
163. Wang C, Lu R, Ouyang X, Ho MW, Chia W, Yu F, and Lim KL. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J Neurosci 27: 8563-8570, 2007.
164. Wang D, Qian L, Xiong H, Liu J, Neckameyer WS, Oldham S, Zia K, wang J, Bodmer R, and Zhang Z. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci USA 103: 13520-13525, 2006.
165. Wang HL, Chou AH, Yeh TH, Li AH, Chen YL, Kuo YL, Tsai SR, and Yu ST. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 28: 216-226, 2007.
166. Weihofen A, Ostaszewski B, Minami Y, and Selkoe DJ. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet 17: 602-616, 2008.
167. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, and Dawson TM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102: 16842-16847, 2005.
168. Whitworth AJ, Lee JR, Ho VM, Flick R, Chowdhury R, and McQuibban GA. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Dis Model Mech 1: 168-174, 2008.
169. Wood-Kaczmar A, Gandhi S, and Wood NW. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12: 521-528, 2006.
170. Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AS, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas F, Downward J, Mansfield I, Jat P, Taylor J, Heales S, Duchen MR, Latchman D, Tabrizi SH, and Wood NW. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 3: e2455, 2008.
171. Wyss-Coray T and Mucke L. Inflammation in neurodegenerative disease - A double-edged sword. Neuron 35: 419-432, 2002.
172. Yamamoto A, Friedlein A, Imai Y, Takahashi R, Kahle PJ, and Haass C. Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem 280: 3390-3399, 2005.
173. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang I, Beal MF, Voel H, and Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 103: 10793-10798, 2006.
174. Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban A, Vogel J, and Lu B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA 105: 7070-7075, 2008.
175. Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, and Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312: 1342-1348, 2003.
176. Zeng BY, Bukhatwa S, Hikima A, Rose S, and Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol 60: 248-252, 2006.
177. Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI, Torp R, Torgner IA, Ottersen OP, Dawson TM, and Dawson VL. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14: 2063-2073, 2005.
178. Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, and Xia XG. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 3: 242-250, 2007.
179. Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P, Strongosky A, Kacergus J, Calne DB, Stoessl J, Uitti RJ, Pfeiffer RF, Trenwakder C, Homann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, and Gasser T. The PARK8 locus in autosomal dominant parkinsonism: Confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 74: 11-19, 2004.
180. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evfrafoc O, Jonghe PD, Takahasi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timemrman V, Schroder JM, and Vance JM. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36: 449-451, 2004.